A 503A pharmacy is a traditional compounding pharmacy that prepares custom medications for individual patients based on a valid prescription. The “503A” refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, added in 1997, which allows licensed pharmacists and physicians to compound drugs without needing the same FDA approval process that commercial drug manufacturers go through. In exchange for that flexibility, these pharmacies must follow specific rules, the most important being that every compounded product is tied to a specific, named patient.
How 503A Pharmacies Differ From Regular Pharmacies
A standard retail pharmacy dispenses mass-manufactured medications that have gone through the full FDA approval process. A 503A pharmacy, by contrast, creates medications from scratch. This is useful when a patient needs something that isn’t commercially available: a liquid version of a drug that only comes in tablets, a formulation without a specific allergen, or a combination of ingredients in a particular strength.
The key legal trade-off is straightforward. Because 503A pharmacies make small batches for individual patients rather than mass-producing drugs, they’re exempt from three major FDA requirements: current good manufacturing practice (cGMP) standards that apply to large manufacturers, the standard drug labeling rules, and the formal new drug approval process. They still must follow compounding quality standards set by the United States Pharmacopeia, known as USP chapters 795 (for non-sterile preparations), 797 (for sterile preparations), and 800 (for handling hazardous drugs).
The Prescription Requirement
The defining feature of a 503A pharmacy is that it compounds drugs only for identified individual patients. Every medication leaving the facility must be tied to a valid, patient-specific prescription from a licensed prescriber. The prescription must clearly identify the patient by name. If the patient’s identity isn’t given or isn’t clear, the pharmacy doesn’t meet the legal requirement.
There is a narrow exception that allows pharmacists to compound limited quantities of a medication before receiving a prescription, but only when there’s an established history of receiving prescriptions for that product and an existing relationship with either the patient or the prescriber. This lets pharmacies keep small amounts of commonly requested compounds on hand to avoid delays, not to stockpile products for general distribution.
What 503A Pharmacies Can and Cannot Compound
The ingredients a 503A pharmacy can use are restricted. Bulk drug substances must meet one of three criteria: they comply with an official USP or National Formulary monograph, they’re components of an FDA-approved drug product, or they appear on the FDA’s specific list of approved bulk substances for 503A compounding. Every bulk substance must also come with a valid certificate of analysis from a manufacturer registered with the FDA.
503A pharmacies also cannot regularly produce drugs that are “essentially copies” of commercially available products. The FDA considers a compounded drug essentially a copy if it contains the same active ingredient in the same or similar strength and is used by the same route of administration as a commercial product. A prescriber can override this restriction by documenting that the compounded version contains a change that produces a clinically significant difference for a specific patient. Without that documentation, the FDA limits pharmacies to filling four or fewer prescriptions of any such “copy” product per calendar month.
This restriction became especially visible with GLP-1 medications like semaglutide. Many 503A pharmacies had been compounding semaglutide injections, sometimes combining them with other ingredients like vitamin B12. As of April 2025, the FDA’s period of enforcement discretion for compounded semaglutide injections under 503A ended, meaning pharmacies compounding these products now face the standard “essentially a copy” restrictions.
Who Regulates 503A Pharmacies
State boards of pharmacy are the primary regulators of 503A compounding pharmacies. This is one of the biggest distinctions between 503A and 503B facilities. Unlike 503B outsourcing facilities, 503A pharmacies are not required to register with the FDA or report adverse events to the agency.
That said, the FDA does not ignore them entirely. The agency conducts inspections of 503A facilities using a risk-based approach, prioritizing pharmacies based on factors like prior complaints. These inspections evaluate whether the pharmacy is meeting Section 503A conditions and whether there are any unsanitary conditions. When the FDA finds problems, it typically refers the findings to state regulators to oversee corrective actions. Before inspections, the FDA’s Office of Regulatory Affairs generally invites state regulators to participate.
503A vs. 503B: The Core Differences
The distinction matters if you’re a patient receiving compounded medications or a prescriber choosing where to source them.
- Scale: 503A pharmacies make patient-specific medications in small quantities. 503B outsourcing facilities produce compounded drugs in larger batches, essentially functioning as small-scale manufacturers.
- Prescription requirement: 503A pharmacies need a patient-specific prescription for every product. 503B facilities can distribute compounded drugs without individual prescriptions, supplying hospitals and clinics with stock for “office use.”
- Quality standards: 503A pharmacies follow USP compounding standards. 503B facilities must meet the stricter cGMP requirements that apply to drug manufacturers.
- Oversight: 503A pharmacies are primarily regulated by state boards. 503B facilities register with the FDA, undergo routine FDA surveillance inspections, and must report adverse events.
- Customization: If you need a product tailored to a specific patient, such as a unique flavor, dosage form, or suspension, a 503A pharmacy is generally better equipped. 503B facilities aren’t designed for small, one-off preparations.
Why the 503A Category Exists
Pharmacy compounding has existed for as long as pharmacies have, but the formal legal framework took shape relatively recently. Congress created Section 503A through the FDA Modernization Act of 1997 to clarify when traditional compounding was permissible without full FDA drug approval.
The companion category, 503B, came later. In 2012, contaminated steroid injections from the New England Compounding Center caused a fungal meningitis outbreak that affected more than 800 people across 23 states and killed 64. Congress responded with the Drug Quality and Security Act of 2013, which created Section 503B as a new, more heavily regulated category for facilities that compound on a larger scale. The law essentially drew a clear line: small-scale, patient-specific compounding stays under 503A with state oversight, while larger-scale operations must register as 503B outsourcing facilities and submit to direct FDA regulation.